Skip to Content

FluLaval Quadrivalent Approval History

  • FDA approved: Yes (First approved August 16th, 2013)
  • Brand name: FluLaval Quadrivalent
  • Generic name: influenza virus vaccine
  • Company: GlaxoSmithKline
  • Treatment for: Influenza Prophylaxis

FluLaval Quadrivalent (influenza virus vaccine) is a vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Development History and FDA Approval Process for FluLaval Quadrivalent

Nov 18, 2016Approval GSK Receives FDA Approval for Expanded Indication for FluLaval Quadrivalent (Influenza Vaccine) for Infants 6 Months and Older
Aug 16, 2013Approval FDA Approves FluLaval Quadrivalent
Oct  5, 2006Approval FDA Approves FluLaval for Upcoming Influenza Season
Mar 23, 2006GlaxoSmithKline Submits Biologics License Application for FDA Approval of FluLaval

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.